Shiqin Liu

Title(s)Assistant Adjunct Professor, Molecular and Medical Pharmacology
SchoolMedicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, Los Angeles, CA, USAPostdoctoral Fellow02/2024Cancer Biology (Stoyanova Lab)
    Stanford University, CA, USAPostdoctoral Fellow01/2023Cancer Biology (Stoyanova Lab))
    Central South University, ChinaResidency03/2019Surgery
    Peking University, ChinaPhD07/2017Oncology
    University of Miami, FL, USAJoint PhD09/2016Surgery
    Central South University, ChinaMD07/2012Clinical Medicine
    Collapse Awards and Honors
    Society for Basic Urologic Research Annual Conference2024Travel Award
    Jonsson Comprehensive Cancer Center, UCLA2024Travel Award
    Society for Basic Urologic Research Annual Conference2023EULA and Donald S. Coffey Innovative Research Award
    Jonsson Comprehensive Cancer Center, UCLA2023  - 2024Postdoc Fellowship
    Maternal & Child Health Research Institute, Stanford University2022  - 2023Postdoc Award
    No. 82102809, National Natural Science Foundation of China 2019  - 2022Young Investigator Award
    Society for Basic Urologic Research Annual Conference2021Travel Award
    Stanford University2021  - 2022Justice, Diversity, Equity & Inclusion Seed Grants

    Collapse Overview 
    Collapse Overview
    As a clinician-scientist, I focus on developing novel biomarkers and therapeutic strategies for advanced diseases with translational potential. My research interests are identifying new molecular mechanisms underlying cancer development, improving cancer early detection, and discovering molecular-based therapeutic strategies for clinically significant diseases.

    My research focuses on the development of novel tissue and blood-based biomarkers that can be used in clinical practice to improve the stratification and prediction of high-risk diseases. I am developing new antibody-targeted therapies and optical imaging agents for epithelial cancers. I use proteomic approaches and high-throughput screening to identify molecular-based therapeutic targets, new small-molecule inhibitors, and combination therapeutic strategies for lethal cancers.

    Collapse Research 
    Collapse Research Activities and Funding
    Developing New Cell-Mediated Immunotherapeutic Strategies for Small-Cell Lung Cancer
    Department of Defense HT94252510049Feb 1, 2025 - Jan 31, 2026
    Role: PI
    Description: The major goal is to develop new UCH-L1-targeted immunotherapy for SCLC to expand targeted immunotherapy options for this lethal disease.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ubiquitin C-terminal hydrolase L1 is a regulator of tumor growth and metastasis in double-negative prostate cancer. Am J Clin Exp Urol. 2024; 12(5):306-322. Liu S, Garcia-Marques FJ, Shen M, Bermudez A, Pitteri SJ, Stoyanova T. PMID: 39584005; PMCID: PMC11578776.
      View in: PubMed   Mentions:
    2. Identification of a 5-gene signature panel for the prediction of prostate cancer progression. Br J Cancer. 2024 Dec; 131(11):1748-1761. Shen M, García-Marqués F, Muruganantham A, Liu S, White JR, Bermudez A, Rice MA, Thompson K, Chen CL, Hung CN, Zhang Z, Huang TH, Liss MA, Pienta KJ, Pitteri SJ, Stoyanova T. PMID: 39402324; PMCID: PMC11589118.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Protocol for establishing spontaneous metastasis in mice using a subcutaneous tumor model. STAR Protoc. 2024 Sep 20; 5(3):103239. Liu S, Shen M, Le K, Hartono AB, Stoyanova T. PMID: 39096496; PMCID: PMC11342759.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    4. Co-axial hydrogel spinning for facile biofabrication of prostate cancer-like 3D models. Biofabrication. 2024 02 20; 16(2). Guimarães CF, Liu S, Wang J, Purcell E, Ozedirne T, Ren T, Aslan M, Yin Q, Reis RL, Stoyanova T, Demirci U. PMID: 38306674.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    5. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. Cell Rep Med. 2024 Feb 20; 5(2):101381. Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu EC, Shen M, Shaw Toland AM, Bermudez A, Hartono AB, Massey CF, Lee CS, Zheng L, Baron M, Denning CJ, Aslan M, Nguyen HM, Nolley R, Zoubeidi A, Das M, Kunder CA, Howitt BE, Soh HT, Weissman IL, Liss MA, Chin AI, Brooks JD, Corey E, Pitteri SJ, Huang J, Stoyanova T. PMID: 38244540; PMCID: PMC10897521.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    6. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. Sci Rep. 2024 01 04; 14(1):486. Liu S, Hawley SJ, Kunder CA, Hsu EC, Shen M, Westphalen L, Auman H, Newcomb LF, Lin DW, Nelson PS, Feng Z, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Simko J, Gleave ME, Troyer DA, McKenney JK, Brooks JD, Liss MA, Stoyanova T. PMID: 38177207; PMCID: PMC10766957.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy. Proc Natl Acad Sci U S A. 2023 Nov 21; 120(47):e2312374120. Bangayan NJ, Wang L, Burton Sojo G, Noguchi M, Cheng D, Ta L, Gunn D, Mao Z, Liu S, Yin Q, Riedinger M, Li K, Wu AM, Stoyanova T, Witte ON. PMID: 37963244; PMCID: PMC10666036.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    8. ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype. Br J Cancer. 2023 11; 129(11):1818-1828. Shen M, Liu S, Toland A, Hsu EC, Hartono AB, Alabi BR, Aslan M, Nguyen HM, Sessions CJ, Nolley R, Shi C, Huang J, Brooks JD, Corey E, Stoyanova T. PMID: 37798372; PMCID: PMC10667239.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    9. Proteomics analysis of urine and catheter-associated biofilms in spinal cord injury patients. Am J Clin Exp Urol. 2023; 11(3):206-219. Garcia-Marques FJ, Zakrasek E, Bermudez A, Polasko AL, Liu S, Stoyanova T, Brooks JD, Lavelle J, Pitteri SJ. PMID: 37441441; PMCID: PMC10333135.
      View in: PubMed   Mentions:
    10. Multimodal In Vivo Tracking of Chimeric Antigen Receptor T Cells in Preclinical Glioblastoma Models. Invest Radiol. 2023 06 01; 58(6):388-395. Wu WE, Chang E, Jin L, Liu S, Huang CH, Kamal R, Liang T, Aissaoui NM, Theruvath AJ, Pisani L, Moseley M, Stoyanova T, Paulmurugan R, Huang J, Mitchell DA, Daldrup-Link HE. PMID: 36729074; PMCID: PMC10164035.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    11. Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther. 2022 10; 238:108255. Alabi BR, Liu S, Stoyanova T. PMID: 35905791.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    12. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin Cancer Biol. 2022 11; 86(Pt 3):57-68. Liu S, Alabi BR, Yin Q, Stoyanova T. PMID: 35597438.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    13. Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway. Cell Death Dis. 2022 03 02; 13(3):195. Bai F, Wang C, Liu X, Hollern D, Liu S, Fan C, Liu C, Ren S, Herschkowitz JI, Zhu WG, Pei XH. PMID: 35236825; PMCID: PMC8891277.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    14. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Rep Med. 2022 02 15; 3(2):100502. Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu EC, Liu S, Bermudez A, Kanchustambham V, Shankar V, Inde Z, Alabi BR, Muruganantham A, Shen M, Pandrala M, Nolley R, Aslan M, Ghoochani A, Agarwal A, Buckup M, Kumar M, Going CC, Peehl DM, Dixon SJ, Zare RN, Brooks JD, Pitteri SJ, Malhotra SV, Stoyanova T. PMID: 35243415; PMCID: PMC8861828.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    15. Protein signatures to distinguish aggressive from indolent prostate cancer. Prostate. 2022 04; 82(5):605-616. Garcia-Marques F, Liu S, Totten SM, Bermudez A, Tanimoto C, Hsu EC, Nolley R, Hembree A, Stoyanova T, Brooks JD, Pitteri SJ. PMID: 35098564; PMCID: PMC8916040.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    16. Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer. Methods Mol Biol. 2022; 2472:221-233. Liu S, Hsu EC, Shen M, Aslan M, Stoyanova T. PMID: 35674904.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    17. Loss of function of GATA3 induces basal-like mammary tumors. Theranostics. 2022; 12(2):720-733. Bai F, Zheng C, Liu X, Chan HL, Liu S, Ma J, Ren S, Zhu WG, Pei XH. PMID: 34976209; PMCID: PMC8692904.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    18. Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer. 2021 Oct 28; 7(1):141. Aslan M, Hsu EC, Garcia-Marques FJ, Bermudez A, Liu S, Shen M, West M, Zhang CA, Rice MA, Brooks JD, West R, Pitteri SJ, Gyorffy B, Stoyanova T. PMID: 34711841; PMCID: PMC8553750.
      View in: PubMed   Mentions: 23  
    19. Engineering Polysaccharide-Based Hydrogel Photonic Constructs: From Multiscale Detection to the Biofabrication of Living Optical Fibers. Adv Mater. 2021 Dec; 33(52):e2105361. Guimarães CF, Ahmed R, Mataji-Kojouri A, Soto F, Wang J, Liu S, Stoyanova T, Marques AP, Reis RL, Demirci U. PMID: 34617338.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    20. Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay. Biol Methods Protoc. 2021; 6(1):bpab014. Aslan M, Hsu EC, Liu S, Stoyanova T. PMID: 34377838; PMCID: PMC8346651.
      View in: PubMed   Mentions: 11  
    21. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Sci Rep. 2021 06 25; 11(1):13305. Hsu EC, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, Nguyen HM, Nolley R, Pitteri SJ, Corey E, Brooks JD, Stoyanova T. PMID: 34172788; PMCID: PMC8233352.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    22. Circular RNA circHIPK3 promotes breast cancer progression via sponging MiR-326. Cell Cycle. 2021 07; 20(13):1320-1333. Luo N, Liu S, Li X, Hu Y, Zhang K. PMID: 34152928; PMCID: PMC8331001.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    23. Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay. Sci Rep. 2021 04 07; 11(1):7612. Liu S, Garcia-Marques F, Zhang CA, Lee JJ, Nolley R, Shen M, Hsu EC, Aslan M, Koul K, Pitteri SJ, Brooks JD, Stoyanova T. PMID: 33828176; PMCID: PMC8027881.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    24. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol. 2021; 9(1):73-87. Shen M, Liu S, Stoyanova T. PMID: 33816696; PMCID: PMC8012837.
      View in: PubMed   Mentions: 18  
    25. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors. Breast Cancer Res. 2021 01 21; 23(1):10. Bai F, Liu S, Liu X, Hollern DP, Scott A, Wang C, Zhang L, Fan C, Fu L, Perou CM, Zhu WG, Pei XH. PMID: 33478572; PMCID: PMC7819225.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    26. Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. Br J Cancer. 2021 03; 124(5):896-900. Liu S, Shen M, Hsu EC, Zhang CA, Garcia-Marques F, Nolley R, Koul K, Rice MA, Aslan M, Pitteri SJ, Massie C, George A, Brooks JD, Gnanapragasam VJ, Stoyanova T. PMID: 33288843; PMCID: PMC7921397.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    27. Plectin is a regulator of prostate cancer growth and metastasis. Oncogene. 2021 01; 40(3):663-676. Buckup M, Rice MA, Hsu EC, Garcia-Marques F, Liu S, Aslan M, Bermudez A, Huang J, Pitteri SJ, Stoyanova T. PMID: 33219316; PMCID: PMC8078627.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    28. LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis. Biosci Rep. 2020 07 31; 40(7). Liu SQ, Zhou ZY, Dong X, Guo L, Zhang KJ. PMID: 32538432; PMCID: PMC7327181.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    29. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci U S A. 2020 01 28; 117(4):2032-2042. Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, Ghoochani A, Zhang CA, Chen YS, Zlitni A, Kumar S, Nolley R, Habte F, Shen M, Koul K, Peehl DM, Zoubeidi A, Gambhir SS, Kunder CA, Pitteri SJ, Brooks JD, Stoyanova T. PMID: 31932422; PMCID: PMC6994991.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimalsCells
    30. p16 loss rescues functional decline of Brca1-deficient mammary stem cells. Cell Cycle. 2017 Apr 18; 16(8):759-764. Scott A, Bai F, Chan HL, Liu S, Slingerland JM, Robbins DJ, Capobianco AJ, Pei XH. PMID: 28278054; PMCID: PMC5405722.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    31. A specific immune tolerance toward offspring cells is to exist after the mother lymphocyte infusion. Immunobiology. 2017 04; 222(4):658-663. Xing H, Liu S, Chen X, Fang F, Wu X, Zhu P. PMID: 28065449.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    32. p16INK4a suppresses BRCA1-deficient mammary tumorigenesis. Oncotarget. 2016 Dec 20; 7(51):84496-84507. Scott A, Bai F, Chan HL, Liu S, Ma J, Slingerland JM, Robbins DJ, Capobianco AJ, Pei XH. PMID: 27811360; PMCID: PMC5356676.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    33. Gata3 restrains B cell proliferation and cooperates with p18INK4c to repress B cell lymphomagenesis. Oncotarget. 2016 Sep 27; 7(39):64007-64020. Liu S, Chan HL, Bai F, Ma J, Scott A, Robbins DJ, Capobianco AJ, Zhu P, Pei XH. PMID: 27588406; PMCID: PMC5325421.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    34. [Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr; 22(2):349-56. Hu Y, Chen Y, Wang LH, Chen X, Fang F, Liu SQ, Wu XQ, Zhu P. PMID: 24763004.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    35. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients. Chin Med J (Engl). 2014; 127(15):2765-70. Hu Y, Wang M, Chen Y, Chen X, Fang F, Liu S, Zhang Y, Wu X, Zhu P. PMID: 25146610.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    Shiqin's Networks
    Concepts (175)
    Derived automatically from this person's publications.
    _
    Co-Authors (7)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _